Suchergebnisse - "Meissner, H Cody"

PubPharm (13)

1

The Beginning of a New Era in RSV Control

enthalten in: Pediatrics | 2023

von Meissner, H.

CommentOn: Pediatrics. 2023 Nov 1;152(5):. - PMID 37641189

2

Utilization of chronic lung disease treatment before the respiratory syncytial virus season as palivizumab prophylaxis qualifier in the American Academy of Pediatrics Guidelines

enthalten in: European journal of pediatrics | 2022

von Choi, Y. | Meissner, H. | Hampp, C. | +2

3

Calibration of Chronic Lung Disease Severity as a Risk Factor for Respiratory Syncytial Virus Hospitalization

enthalten in: Journal of the Pediatric Infectious Diseases Society | 2021

von Choi, Y. | Meissner, H. | Hampp, C. | +3

4

Respiratory Syncytial Virus : A Byzantine Pathogen

enthalten in: The Journal of pediatrics | 2016

von Meissner, H. | Brady, M.

CommentOn: J Pediatr. 2016 Apr;171:31-7. - PMID 26724119

5

Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection

enthalten in: Pediatrics | 2014

von American Academy of Pediatrics Committee on Infectious Diseases | American Academy of Pediatrics Bronchiolitis Guidelines Committee | Brady, M. | +26

6

Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection

enthalten in: Pediatrics | 2014

von American Academy of Pediatrics Committee on Infectious Diseases | American Academy of Pediatrics Bronchiolitis Guidelines Committee | Brady, M. | +26

ErratumIn: Pediatrics. 2014 Dec;134(6):1221

7

RSV immunoprophylaxis : does the benefit justify the cost?

enthalten in: Pediatrics | 2013

von Meissner, H. | Kimberlin, D.

CommentOn: Pediatrics. 2013 Nov;132(5):811-8. - PMID 24127479

8

The role of immunoprophylaxis in the reduction of disease attributable to respiratory syncytial virus

enthalten in: Pediatrics | 2009

von Meissner, H. | Bocchini, J. | Brady, M. | +3

9

From the American Academy of Pediatrics : Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections

enthalten in: Pediatrics | 2009

von Committee on Infectious Diseases | Bocchini, J. | Bernstein, H. | +31

CommentIn: Pediatrics. 2010 Apr;125(4):e1021; author reply e1022. - PMID 20360416

10

Annual variation in respiratory syncytial virus season and decisions regarding immunoprophylaxis with palivizumab

enthalten in: Pediatrics | 2004

von Meissner, H. | Anderson, L. | Pickering, L.

CommentOn: Pediatrics. 1998 Sep;102(3 Pt 1):531-7. - PMID 9738173